Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Zanchetti, A ^a   Omboni, S ^b   Di Biagio, C ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Candesartan cilexetil; Clinical study; Enalapril

Indexed keywords

CANDESARTAN HEXETIL; ENALAPRIL;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030699197     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997; 32: 1-29.
2. Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II blocker. J Hum Hypertens 1997; 11 (Suppl 2): S91-S95.